WuXi Biologics to Acquire Pfizer's Pharma Plant in Hangzhou, China, an Industrial Info Market Brief

---

WuXi Biologics is preparing to acquire a 50,000-square-meter bio-pharmaceutical production base in Hangzhou, China, from Pfizer. The plant cost Pfizer $3.5 billion and began production in 2018, featuring an original solution production line and two preparation production lines.

Following the acquisition, WuXi Biologics will add three new factories: a solution factory (MFG20, totaling 4,000 liters, possibly to be expanded to 8,000 liters); a preparation factory for DP9 and vials; and a preparation factory for DP10 and prefilled needles.

Industrial Info is tracking six operational Pfizer plants in mainland China. Click here for a list, and see Industrial Info's Geolocator heat map below.